Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity

DMM Disease Models and Mechanisms

Volumn 7, Issue 5, 2014, Pages 571-582

  O'Donnell, Kelley C ^a   Lulla, Aaron ^b   Stahl, Mark C ^b   Wheat, Nickolas D ^a   Bronstein, Jeff M ^b,c   Sagasti, Alvaro ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alpha synuclein; Axon; Mitochondria; Neurodegeneration; PGC1 ; Zebrafish

Indexed keywords

ALPHA SYNUCLEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR-1ALPHA, ZEBRAFISH; TRANSCRIPTION FACTOR; ZEBRAFISH PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXONAL INJURY; BIOGENESIS; CELL DEATH; CELL STRUCTURE; DETOXIFICATION; HUMAN; IN VIVO STUDY; MITOCHONDRION; NERVE CELL; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; NEUROPATHY; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NERVE CELL; WALLERIAN DEGENERATION; ZEBRA FISH; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FERTILIZATION; LARVA; METABOLISM; NERVE DEGENERATION; NERVE FIBER; PATHOLOGY; PROTEIN TRANSPORT; TOXICITY;

ALPHA-SYNUCLEIN; ANIMALS; AXONS; CELL DEATH; DISEASE MODELS, ANIMAL; FERTILIZATION; HUMANS; LARVA; MITOCHONDRIA; NERVE DEGENERATION; PROTEIN TRANSPORT; SENSORY RECEPTOR CELLS; TRANSCRIPTION FACTORS; WALLERIAN DEGENERATION; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84900434854     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.013185     Document Type: Article

References (128)

1. Anderson, R. and Prolla, T. (2009). PGC-1alpha in aging and anti-aging interventions. Biochim. Biophys. Acta 1790, 1059-1066.
2. Antenor-Dorsey, J. A. and O'Malley, K. L. (2012). WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity. Mol. Neurodegener. 7, 5.
3. Arnold, B., Cassady, S. J., VanLaar, V. S. and Berman, S. B. (2011). Integrating multiple aspects of mitochondrial dynamics in neurons: age-related differences and dynamic changes in a chronic rotenone model. Neurobiol. Dis. 41, 189-200.
4. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. and Bonini, N. M. (2002). Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868. (Pubitemid 34118369)
5. Avery, M. A., Rooney, T. M., Pandya, J. D., Wishart, T. M., Gillingwater, T. H., Geddes, J. W., Sullivan, P. G. and Freeman, M. R. (2012). WldS prevents axon degeneration through increased mitochondrial flux and enhanced mitochondrial Ca2+ buffering. Curr. Biol. 22, 596-600.
6. Baloh, R. H., Schmidt, R. E., Pestronk, A. and Milbrandt, J. (2007). Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J. Neurosci. 27, 422-430. (Pubitemid 46106016)
7. Bandmann, O. and Burton, E. A. (2010). Genetic zebrafish models of neurodegenerative diseases. Neurobiol. Dis. 40, 58-65.
8. Banerjee, K., Sinha, M., Pham, C. L., Jana, S., Chanda, D., Cappai, R. and Chakrabarti, S. (2010). Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease. FEBS Lett. 584, 1571-1576.
9. Barrientos, S. A., Martinez, N. W., Yoo, S., Jara, J. S., Zamorano, S., Hetz, C., Twiss, J. L., Alvarez, J. and Court, F. A. (2011). Axonal degeneration is mediated by the mitochondrial permeability transition pore. J. Neurosci. 31, 966-978.
10. Beirowski, B., Nógrádi, A., Babetto, E., Garcia-Alias, G. and Coleman, M. P. (2010). Mechanisms of axonal spheroid formation in central nervous system Wallerian degeneration. J. Neuropathol. Exp. Neurol. 69, 455-472.
11. Benard, G. and Rossignol, R. (2008). Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. Antioxid. Redox Signal. 10, 1313-1342.
12. Boassa, D., Berlanga, M. L., Yang, M. A., Terada, M., Hu, J., Bushong, E. A., Hwang, M., Masliah, E., George, J. M. and Ellisman, M. H. (2013). Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis. J. Neurosci. 33, 2605-2615.
13. Braak, H., Sandmann-Keil, D., Gai, W. and Braak, E. (1999). Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alphasynuclein immunocytochemistry. Neurosci. Lett. 265, 67-69. (Pubitemid 29210200)
14. Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N. and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. (Pubitemid 36007810)
15. Bretaud, S., Lee, S. and Guo, S. (2004). Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease. Neurotoxicol. Teratol. 26, 857-864. (Pubitemid 39296769)
16. Brustovetsky, N., Brustovetsky, T., Jemmerson, R. and Dubinsky, J. M. (2002). Calcium-induced cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane. J. Neurochem. 80, 207-218. (Pubitemid 34809366)
17. Brustovetsky, N., Brustovetsky, T., Purl, K. J., Capano, M., Crompton, M. and Dubinsky, J. M. (2003). Increased susceptibility of striatal mitochondria to calciuminduced permeability transition. J. Neurosci. 23, 4858-4867. (Pubitemid 36793212)
18. Burke, R. E. and O'Malley, K. (2013). Axon degeneration in Parkinson's disease. Exp. Neurol. 246, 72-83. PubMed
19. Butler, E. K., Voigt, A., Lutz, A. K., Toegel, J. P., Gerhardt, E., Karsten, P., Falkenburger, B., Reinartz, A., Winklhofer, K. F. and Schulz, J. B. (2012). The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity. PLoS Genet. 8, e1002488.
20. Cai, Q., Zakaria, H. M., Simone, A. and Sheng, Z. H. (2012). Spatial parkin translocation and degradation of damaged mitochondria via mitophagy in live cortical neurons. Curr. Biol. 22, 545-552.
21. Calì, T., Ottolini, D., Negro, A. and Brini, M. (2012). α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulummitochondria interactions. J. Biol. Chem. 287, 17914-17929.
22. Cardoso, S. M. (2011). The mitochondrial cascade hypothesis for Parkinson's disease. Curr. Pharm. Des. 17, 3390-3397.
23. Cartelli, D., Ronchi, C., Maggioni, M. G., Rodighiero, S., Giavini, E. and Cappelletti, G. (2010). Microtubule dysfunction precedes transport impairment and mitochondria damage in MPP+ -induced neurodegeneration. J. Neurochem. 115, 247-258.
24. Cassarino, D. S., Fall, C. P., Swerdlow, R. H., Smith, T. S., Halvorsen, E. M., Miller, S. W., Parks, J. P., Parker, W. D., Jr and Bennett, J. P., Jr (1997). Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362, 77-86. (Pubitemid 28027114)
25. Cheng, H. C. and Burke, R. E. (2010). The Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo. J. Neurochem. 113, 683-691.
26. Chesselet, M. F. (2008). In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp. Neurol. 209, 22-27.
27. Chinta, S. J., Mallajosyula, J. K., Rane, A. and Andersen, J. K. (2010). Mitochondrial á-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 486, 235-239.
28. Coleman, M. P., Conforti, L., Buckmaster, E. A., Tarlton, A., Ewing, R. M., Brown, M. C., Lyon, M. F. and Perry, V. H. (1998). An 85-kb tandem triplication in the slow Wallerian degeneration (Wlds) mouse. Proc. Natl. Acad. Sci. USA 95, 9985-9990.
29. Costantini, P., Chernyak, B. V., Petronilli, V. and Bernardi, P. (1996). Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J. Biol. Chem. 271, 6746-6751. (Pubitemid 26104106)
30. Decressac, M., Mattsson, B., Lundblad, M., Weikop, P. and Björklund, A. (2012). Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Neurobiol. Dis. 45, 939-953.
31. Devi, L. and Anandatheerthavarada, H. K. (2010). Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim. Biophys. Acta 1802, 11-19.
32. Dodson, M. W. and Guo, M. (2007). Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr. Opin. Neurobiol. 17, 331-337. (Pubitemid 46880329)
33. Donnelly, M. L., Luke, G., Mehrotra, A., Li, X., Hughes, L. E., Gani, D. and Ryan, M. D. (2001). Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J. Gen. Virol. 82, 1013-1025. (Pubitemid 32454602)
34. Exner, N., Lutz, A. K., Haass, C. and Winklhofer, K. F. (2012). Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31, 3038-3062.
35. Feany, M. B. and Bender, W. W. (2000). A Drosophila model of Parkinson's disease. Nature 404, 394-398. (Pubitemid 30164341)
36. Fernagut, P. O. and Chesselet, M. F. (2004). Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 17, 123-130.
37. Fleming, S. M., Salcedo, J., Fernagut, P. O., Rockenstein, E., Masliah, E., Levine, M. S. and Chesselet, M. F. (2004). Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24, 9434-9440. (Pubitemid 39426179)
38. Flinn, L., Bretaud, S., Lo, C., Ingham, P. W. and Bandmann, O. (2008). Zebrafish as a new animal model for movement disorders. J. Neurochem. 106, 1991-1997.
39. Fuchs, J., Nilsson, C., Kachergus, J., Munz, M., Larsson, E. M., Schüle, B., Langston, J. W., Middleton, F. A., Ross, O. A., Hulihan, M. et al. (2007). Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68, 916-922. (Pubitemid 46568503)
40. Galvin, J. E., Uryu, K., Lee, V. M. and Trojanowski, J. Q. (1999). Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. USA 96, 13450-13455.
41. Goldberg, J. A., Guzman, J. N., Estep, C. M., Ilijic, E., Kondapalli, J., Sanchez-Padilla, J. and Surmeier, D. J. (2012). Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat. Neurosci. 15, 1414-1421.
42. Gu, Z., Nakamura, T. and Lipton, S. A. (2010). Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol. Neurobiol. 41, 55-72.
43. Gunter, T. E., Gunter, K. K., Sheu, S. S. and Gavin, C. E. (1994). Mitochondrial calcium transport: physiological and pathological relevance. Am. J. Physiol. 267, C313-C339.
44. Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T. and Surmeier, D. J. (2010). Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696-700.
45. Hanai, J., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S., Yamashita, M., Phillips, P. S., Sukhatme, V. P. et al. (2007). The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J. Clin. Invest. 117, 3940-3951. (Pubitemid 350224103)
46. Handschin, C. (2009). The biology of PGC-1α and its therapeutic potential. Trends Pharmacol. Sci. 30, 322-329.
47. Hasbani, D. M. and O'Malley, K. L. (2006). Wld(S) mice are protected against the Parkinsonian mimetic MPTP. Exp. Neurol. 202, 93-99. (Pubitemid 44344251)
48. Haworth, R. A. and Hunter, D. R. (1979). The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch. Biochem. Biophys. 195, 460-467. (Pubitemid 9235078)
49. Herkenham, M., Little, M. D., Bankiewicz, K., Yang, S. C., Markey, S. P. and Johannessen, J. N. (1991). Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40, 133-158.
50. Hornykiewicz, O. (1998). Biochemical aspects of Parkinson's disease. Neurology 51 Suppl. 2, S2-S9.
51. Jellinger, K. A. (2012). Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov. Disord. 27, 8-30.
52. Kamp, F., Exner, N., Lutz, A. K., Wender, N., Hegermann, J., Brunner, B., Nuscher, B., Bartels, T., Giese, A., Beyer, K. et al. (2010). Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 29, 3571-3589.
53. Keeney, P. M., Quigley, C. K., Dunham, L. D., Papageorge, C. M., Iyer, S., Thomas, R. R., Schwarz, K. M., Trimmer, P. A., Khan, S. M., Portell, F. R. et al. (2009). Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum. Gene Ther. 20, 897-907.
54. Kim-Han, J. S., Antenor-Dorsey, J. A. and O'Malley, K. L. (2011). The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J. Neurosci. 31, 7212-7221.
55. Köster, R. W. and Fraser, S. E. (2001). Tracing transgene expression in living zebrafish embryos. Dev. Biol. 233, 329-346. (Pubitemid 32467680)
56. Kowaltowski, A. J., Castilho, R. F. and Vercesi, A. E. (1996). Opening of the mitochondrial permeability transition pore by uncoupling or inorganic phosphate in the presence of Ca2+ is dependent on mitochondrial-generated reactive oxygen species. FEBS Lett. 378, 150-152.
57. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schöls, L. and Riess, O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
58. Kwan, K. M., Fujimoto, E., Grabher, C., Mangum, B. D., Hardy, M. E., Campbell, D. S., Parant, J. M., Yost, H. J., Kanki, J. P. and Chien, C. B. (2007). The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev. Dyn. 236, 3088-3099. (Pubitemid 350175006)
59. Lakso, M., Vartiainen, S., Moilanen, A. M., Sirviö, J., Thomas, J. H., Nass, R., Blakely, R. D. and Wong, G. (2003). Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86, 165-172. (Pubitemid 36753857)
60. Lee, S., Sterky, F. H., Mourier, A., Terzioglu, M., Cullheim, S., Olson, L. and Larsson, N. G. (2012). Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons. Hum. Mol. Genet. 21, 4827-4835.
61. Li, W. W., Yang, R., Guo, J. C., Ren, H. M., Zha, X. L., Cheng, J. S. and Cai, D. F. (2007). Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 18, 1543-1546. (Pubitemid 47476380)
62. Li, L. H., Qin, H. Z., Wang, J. L., Wang, J., Wang, X. L. and Gao, G. D. (2009a). Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Int. Med. Res. 37, 455-463.
63. Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S. et al. (2009b). Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12, 826-828.
64. Lim, K. L. and Ng, C. H. (2009). Genetic models of Parkinson disease. Biochim. Biophys. Acta 1792, 604-615.
65. Liu, S., Sawada, T., Lee, S., Yu, W., Silverio, G., Alapatt, P., Millan, I., Shen, A., Saxton, W., Kanao, T. et al. (2012). Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet. 8, e1002537.
66. Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H. and Gordon, S. (1989). Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur. J. Neurosci. 1, 27-33. (Pubitemid 19142026)
67. Mack, T. G., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L. et al. (2001). Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat. Neurosci. 4, 1199-1206. (Pubitemid 33135625)
68. Maroteaux, L., Campanelli, J. T. and Scheller, R. H. (1988). Synuclein: a neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815.
69. Martin, L. J. (2006). Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 65, 1103-1110.
70. Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L. and Lee, M. K. (2006). Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41-50. (Pubitemid 43089519)
71. Martin, S. M., O'Brien, G. S., Portera-Cailliau, C. and Sagasti, A. (2010). Wallerian degeneration of zebrafish trigeminal axons in the skin is required for regeneration and developmental pruning. Development 137, 3985-3994.
72. Marui, W., Iseki, E., Nakai, T., Miura, S., Kato, M., Uéda, K. and Kosaka, K. (2002). Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J. Neurol. Sci. 195, 153-159. (Pubitemid 34202293)
73. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A. and Mucke, L. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269. (Pubitemid 30112148)
74. Mijatovic, J., Piltonen, M., Alberton, P., Männistö, P. T., Saarma, M. and Piepponen, T. P. (2011). Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals. Neurobiol. Aging 32, 1486-1494.
75. Misgeld, T., Kerschensteiner, M., Bareyre, F. M., Burgess, R. W. and Lichtman, J. W. (2007). Imaging axonal transport of mitochondria in vivo. Nat. Methods 4, 559-561. (Pubitemid 47214773)
76. Misko, A., Jiang, S., Wegorzewska, I., Milbrandt, J. and Baloh, R. H. (2010). Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J. Neurosci. 30, 4232-4240.
77. Misko, A. L., Sasaki, Y., Tuck, E., Milbrandt, J. and Baloh, R. H. (2012). Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J. Neurosci. 32, 4145-4155.
78. Mudò, G., Mäkelä, J., Di Liberto, V., Tselykh, T. V., Olivieri, M., Piepponen, P., Eriksson, O., Mälkiä, A., Bonomo, A., Kairisalo, M. et al. (2012). Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell. Mol. Life Sci. 69, 1153-1165.
79. Nakamura, K., Nemani, V. M., Azarbal, F., Skibinski, G., Levy, J. M., Egami, K., Munishkina, L., Zhang, J., Gardner, B., Wakabayashi, J. et al. (2011). Direct membrane association drives mitochondrial fission by the Parkinson diseaseassociated protein alpha-synuclein. J. Biol. Chem. 286, 20710-20726.
80. Nakata, Y., Yasuda, T., Fukaya, M., Yamamori, S., Itakura, M., Nihira, T., Hayakawa, H., Kawanami, A., Kataoka, M., Nagai, M. et al. (2012). Accumulation of α-synuclein triggered by presynaptic dysfunction. J. Neurosci. 32, 17186-17196.
81. Navarro, A., Boveris, A., Bández, M. J., Sánchez-Pino, M. J., Gómez, C., Muntané, G. and Ferrer, I. (2009). Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic. Biol. Med. 46, 1574-1580.
82. Nikić, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F. M., Brück, W., Bishop, D., Misgeld, T. and Kerschensteiner, M. (2011). A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 17, 495-499.
83. O'Brien, G., Rieger, S., Martin, S., Cavanaugh, A., Portera-Cailliau, C. and Sagasti, A. (2009). Two-photon axotomy and time-lapse confocal imaging in live zebrafish embryos. J. Vis. Exp. 24, pii: 1129. doi: 10.3791/1129.
84. O'Donnell, K. C., Vargas, M. E. and Sagasti, A. (2013). WldS and PGC-1α regulate mitochondrial transport and oxidation state after axonal injury. J. Neurosci. 33, 14778-14790.
85. O'Malley, K. L. (2010). The role of axonopathy in Parkinson's disease. Exp Neurobiol 19, 115-119.
86. Orimo, S., Uchihara, T., Nakamura, A., Mori, F., Kakita, A., Wakabayashi, K. and Takahashi, H. (2008). Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131, 642-650. (Pubitemid 351294710)
87. Pacelli, C., De Rasmo, D., Signorile, A., Grattagliano, I., di Tullio, G., D'Orazio, A., Nico, B., Comi, G. P., Ronchi, D., Ferranini, E. et al. (2011). Mitochondrial defect and PGC-1α dysfunction in parkin-associated familial Parkinson's disease. Biochim. Biophys. Acta 1812, 1041-1053.
88. Palanca, A. M., Lee, S. L., Yee, L. E., Joe-Wong, C., Trinh, L. A., Hiroyasu, E., Husain, M., Fraser, S. E., Pellegrini, M. and Sagasti, A. (2013). New transgenic reporters identify somatosensory neuron subtypes in larval zebrafish. Dev. Neurobiol. 73, 152-167. PubMed
89. Parihar, M. S., Parihar, A., Fujita, M., Hashimoto, M. and Ghafourifar, P. (2008). Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 65, 1272-1284.
90. Penn, A. M., Roberts, T., Hodder, J., Allen, P. S., Zhu, G. and Martin, W. R. (1995). Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 45, 2097-2099.
91. Pham, A. H., Meng, S., Chu, Q. N. and Chan, D. C. (2012). Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum. Mol. Genet. 21, 4817-4826.
92. Plucińska, G., Paquet, D., Hruscha, A., Godinho, L., Haass, C., Schmid, B. and Misgeld, T. (2012). In vivo imaging of disease-related mitochondrial dynamics in a vertebrate model system. J. Neurosci. 32, 16203-16212.
93. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997). Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047. (Pubitemid 27443610)
94. Prabhudesai, S., Sinha, S., Attar, A., Kotagiri, A., Fitzmaurice, A. G., Lakshmanan, R., Ivanova, M. I., Loo, J. A., Klärner, F. G., Schrader, T. et al. (2012). A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 9, 464-476.
95. Press, C. and Milbrandt, J. (2008). Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. J. Neurosci. 28, 4861-4871.
96. Przedborski, S. and Jackson-Lewis, V. (1998). Mechanisms of MPTP toxicity. Mov. Disord. 13 Suppl. 1, 35-38.
97. Reeve, A. K., Park, T. K., Jaros, E., Campbell, G. R., Lax, N. Z., Hepplewhite, P. D., Krishnan, K. J., Elson, J. L., Morris, C. M., McKeith, I. G. et al. (2012). Relationship between mitochondria and α-synuclein: a study of single substantia nigra neurons. Arch. Neurol. 69, 385-393.
98. Ries, V., Silva, R. M., Oo, T. F., Cheng, H. C., Rzhetskaya, M., Kholodilov, N., Flavell, R. A., Kuan, C. Y., Rakic, P. and Burke, R. E. (2008). JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J. Neurochem. 107, 1578-1588.
99. Sai, Y., Zou, Z., Peng, K. and Dong, Z. (2012). The Parkinson's disease-related genes act in mitochondrial homeostasis. Neurosci. Biobehav. Rev. 36, 2034-2043.
100. Sajadi, A., Schneider, B. L. and Aebischer, P. (2004). Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr. Biol. 14, 326-330. (Pubitemid 38300211)
101. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A. et al. (2009). Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307.
102. Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P. and Marsden, C. D. (1990). Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
103. Schulz-Schaeffer, W. J. (2010). The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 120, 131-143.
104. Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. I., Pletinkova, O., Troconso, J. C., Dawson, V. L. and Dawson, T. M. (2011). PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702.
105. Siddiqui, A., Chinta, S. J., Mallajosyula, J. K., Rajagopolan, S., Hanson, I., Rane, A., Melov, S. and Andersen, J. K. (2012). Selective binding of nuclear alphasynuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic. Biol. Med. 53, 993-1003.
106. Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G. et al. (2009). Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312.
107. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841. (Pubitemid 37339619)
108. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R. and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
109. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. and Goedert, M. (1998). alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473. (Pubitemid 28249037)
110. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W. et al. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397-408. (Pubitemid 44572377)
111. Sterky, F. H., Lee, S., Wibom, R., Olson, L. and Larsson, N. G. (2011). Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chaindeficient dopamine neurons in vivo. Proc. Natl. Acad. Sci. USA 108, 12937-12942.
112. Stowers, R. S., Megeath, L. J., Górska-Andrzejak, J., Meinertzhagen, I. A. and Schwarz, T. L. (2002). Axonal transport of mitochondria to synapses depends on milton, a novel Drosophila protein. Neuron 36, 1063-1077. (Pubitemid 36044508)
113. Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J. and Schumacker, P. T. (2011). The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 198, 221-231.
114. Tang, W., Ehrlich, I., Wolff, S. B., Michalski, A. M., Wölfl, S., Hasan, M. T., Lüthi, A. and Sprengel, R. (2009). Faithful expression of multiple proteins via 2A-peptide selfprocessing: a versatile and reliable method for manipulating brain circuits. J. Neurosci. 29, 8621-8629.
115. Tomasiewicz, H. G., Flaherty, D. B., Soria, J. P. and Wood, J. G. (2002). Transgenic zebrafish model of neurodegeneration. J. Neurosci. Res. 70, 734-745. (Pubitemid 35416890)
116. Tsunemi, T. and La Spada, A. R. (2012). PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond. Prog. Neurobiol. 97, 142-151.
117. Uemura, O., Okada, Y., Ando, H., Guedj, M., Higashijima, S., Shimazaki, T., Chino, N., Okano, H. and Okamoto, H. (2005). Comparative functional genomics revealed conservation and diversification of three enhancers of the isl1 gene for motor and sensory neuron-specific expression. Dev. Biol. 278, 587-606. (Pubitemid 40175051)
118. van der Putten, H., Wiederhold, K. H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P., Ruegg, M. A. et al. (2000). Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021-6029.
119. Van Laar, V. S. and Berman, S. B. (2013). The interplay of neuronal mitochondrial dynamics and bioenergetics: Implications for Parkinson's disease. Neurobiol. Dis. 51, 43-55. PubMed
120. Vercesi, A. E., Kowaltowski, A. J., Grijalba, M. T., Meinicke, A. R. and Castilho, R. F. (1997). The role of reactive oxygen species in mitochondrial permeability transition. Biosci. Rep. 17, 43-52. (Pubitemid 27267591)
121. Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., Meaney, D. F., Trojanowski, J. Q. and Lee, V. M. (2011). Exogenous á- synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71.
122. Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y. L., Selkoe, D., Rice, S., Steen, J., LaVoie, M. J. and Schwarz, T. L. (2011). PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147, 893-906.
123. Weihofen, A., Thomas, K. J., Ostaszewski, B. L., Cookson, M. R. and Selkoe, D. J. (2009). Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 48, 2045-2052.
124. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R. C. et al. (1999). Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115-124. (Pubitemid 29331201)
125. Wu-Chou, Y. H., Chen, Y. T., Yeh, T. H., Chang, H. C., Weng, Y. H., Lai, S. C., Huang, C. L., Chen, R. S., Huang, Y. Z., Chen, C. C. et al. (2013). Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: A replication study in a Taiwanese cohort. Parkinsonism Relat. Disord. 19, 251-255.
126. Xie, W. and Chung, K. K. (2012). Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. J. Neurochem. 122, 404-414.
127. Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang-James, Y., Kim, P. D., Hauser, M. A. et al.; Global PD Gene Expression (GPEX) Consortium (2010). PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2, 52ra73.
128. Zhu, M., Li, W. and Lu, C. (2012). Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines. PLoS ONE 7, e36377.